The Utility of Glasgow Prognostic Score and Palliative Prognostic Index in Patients With Head and Neck Squamous Cell Carcinoma Under Palliative Care

Objectives: Palliative care patients with head and neck squamous cell carcinoma (HNSCC) often experience dysphagia and airway trouble; thus, each patient requires a specific palliative care plan based on their prognostication. However, no established specific prognostic tool performed on the day of starting end-of-life care is available for such patients. We assessed the accuracy of Glasgow prognostic score (GPS) and palliative prognostic index (PPI) and their combination to establish a specified prognostic tool for patients with HNSCC in end-of-life setting. Methods: A retrospective clinical chart review was undertaken on patients with HNSCC in end-of life setting who were decided in Kagawa University Hospital and National Hospital Organization Shikoku Cancer Center between April 2011 and March 2019. The patients were divided into 2 categories according to GPS (0-1 and 2) and PPI (groups A-B and C). These were combined into 4 categories (PPI group A-B and GPS score 0-1: good; PPI group A-B and GPS score 2: intermediate; PPI group C and GPS score 2: poor; and PPI group C and GPS score 0-1: others). The survival curves were compared for the former 3 categories. Results: The median survival of the scores 0-1 and 2 on GPS were 114 (72-148) and 39 (25-52) days, respectively ( P < .01). These of groups A-B and C on PPI were 79 (64-99) and 16 (9-29) days, respectively ( P < .01). The median survival of the good, intermediate, and poor categories was 127 (73-149), 64 (44-80), and 15 (9-27) days, respectively ( P < .01 among all categories). Conclusions: In this study, the survival of terminally ill patients with HNSCC can be predicted by the GPS, PPI, and their combination with sufficient probability.

Download Full-text

Feasibility of Use of the Palliative Prognostic Index (PPI) and Glasgow Prognostic Score (GPS) as Prognostic Tools in Patients with Head and Neck Squamous Cell Carcinoma Under Palliative Care

Nippon Jibiinkoka Gakkai Kaiho ◽

10.3950/jibiinkoka.123.729 ◽

2020 ◽

Vol 123 (8) ◽

pp. 729-736

Author(s):

Takehito Kishino ◽

Terushige Mori ◽

Takenori Miyashita ◽

Yohei Ouchi ◽

Yasushi Samukawa ◽

...

Keyword(s):

Palliative Care ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Prognostic Score ◽

Prognostic Index ◽

Glasgow Prognostic Score ◽

Neck Squamous Cell Carcinoma ◽

Palliative Prognostic Index

Download Full-text

Comparison of the accuracy of clinical prediction of survival and palliative prognostic index for patients with head and neck squamous cell carcinoma in the end-of-life setting

Auris Nasus Larynx ◽

10.1016/j.anl.2021.06.003 ◽

2021 ◽

Author(s):

Takehito Kishino ◽

Nobuya Monden ◽

Naoki Akisada ◽

Yuji Hayashi ◽

Masataka Nakamura ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

End Of Life ◽

Squamous Cell ◽

Prognostic Index ◽

Neck Squamous Cell Carcinoma ◽

Clinical Prediction ◽

Prediction Of Survival ◽

Palliative Prognostic Index

Download Full-text

The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care

BMC Palliative Care ◽

10.1186/s12904-015-0011-5 ◽

2015 ◽

Vol 14 (1) ◽

Cited By ~ 17

Author(s):

Wen-Chi Chou ◽

Chen-Yi Kao ◽

Po-Nan Wang ◽

Hung Chang ◽

Hung-Ming Wang ◽

...

Keyword(s):

Palliative Care ◽

Life Expectancy ◽

Charlson Comorbidity Index ◽

Prognostic Score ◽

Prognostic Index ◽

Glasgow Prognostic Score ◽

Hematologic Malignancies ◽

Palliative Prognostic Index ◽

Comorbidity Index

Download Full-text

Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score

European Archives of Oto-Rhino-Laryngology ◽

10.1007/s00405-020-05945-5 ◽

2020 ◽

Vol 277 (8) ◽

pp. 2341-2347 ◽

Cited By ~ 2

Author(s):

Yushi Ueki ◽

Takeshi Takahashi ◽

Hisayuki Ota ◽

Ryusuke Shodo ◽

Keisuke Yamazaki ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Treatment Outcome ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Prognostic Value ◽

Prognostic Score ◽

Performance Status ◽

Glasgow Prognostic Score ◽

Modified Glasgow Prognostic Score

Download Full-text

The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients

Annals of Oncology ◽

10.1093/annonc/mdz252.051 ◽

2019 ◽

Vol 30 ◽

pp. v469-v470 ◽

Cited By ~ 1

Author(s):

R.G. Herrera Gomez ◽

L. Mezquita ◽

E. Auclin ◽

L. Heraudet ◽

M. Plana ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Prognostic Score ◽

Prognostic Index ◽

Metastatic Squamous Cell Carcinoma

Download Full-text

Faculty Opinions recommendation of Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737669931.793573496 ◽

2020 ◽

Author(s):

Heikki Irjala

Keyword(s):

Squamous Cell Carcinoma ◽

Treatment Outcome ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Prognostic Value ◽

Prognostic Score ◽

Performance Status ◽

Glasgow Prognostic Score ◽

Modified Glasgow Prognostic Score

Download Full-text

Real-world effectiveness of Glasgow prognostic score and tumor biomarkers in predicting post-relapse survival in patients with recurrent cervical cancer after minimally invasive surgery

10.21203/rs.3.rs-15854/v1 ◽

2020 ◽

Author(s):

Junhui Guo ◽

Yuanyuan Wang ◽

Xinxin Wang ◽

Shengli Zhou ◽

Peimin Liu

Keyword(s):

Cervical Cancer ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Clinical Data ◽

Squamous Cell ◽

Real World ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Tumor Biomarkers ◽

Recurrent Cervical Cancer

Abstract Background Cervical cancer ranks the third most common malignancy of women worldwide, and recurrence of cervical cancer treatment is the major concern. Carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCCA) and Glasgow Prognostic Score (GPS) were potential prognostic indicator for cervical cancer. However, none of these markers have been evaluated to predict post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Aim To evaluate biomarkers CEA, CA125, SCCA and Glasgow Prognostic Score (GPS) in predicting post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Results Among the 1607 patients, the majority of patients (75.5%) were non-smokers, and the majority of histologic type (68.3%) was squamous cell carcinoma. Except CEA, there were significant difference between different GPS groups in these markers. Areas under the curves (AUC) for GPS, CEA, CA125 and SCCA were 0.632, 0.617, 0.641 and 0.628, respectively. All clinicopathologic characteristics were significantly correlated with CA125. Higher levels of biomarkers and GPS had lower survival and GPS=2 and SCCA was an independent prognostic factor for survival (P=0.008 and P=0.010, respectively). Conclusions In real-world settings, GPS and tumor biomarkers, especially SCCA to independently predict post-recurrence survival in patients with recurrent cervical cancer.

Download Full-text